Menghrajani, K, Gomez-Arteaga, A, Madero-Marroquin, R, Zhang, MJ, Bo-Subait, K, Sanchez, J, Wang, HL, Aljurf, M, Assal, A, Bacher, VU, Badawy, SM, Bejanyan, N, Bhatt, VR, Bredeson, C, Byrne, M, Castillo, P, Cerny, J, Chhabra, S, Ciurea, SO, DeFilipp, Z, Farhadfar, N, Gadalla, S, Gale, RP, Ganguly, S, Gowda, L, Grunwald, MR, Hashmi, S, Hildebrandt, G, Kanakry, CG, Kansagra, A, Khimani, F, Krem, M, Lazarus, H, Liu, HT, Martino, R, Michelis, FV, Nathan, S, Nishihori, T, Olsson, R, Reshef, R, Rizzieri, D, Rowe, JM, Savani, BN, Seo, S, Sharma, A, Solh, M, Ustun, C, Verdonck, LF, Hourigan, C, Sandmaier, B, Litzow, M, Kebriaei, P, Weisdorf, D, Zhang, YM, Tallman, MS, Saber, W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021004881. PMID:34551064. IF:7.500(Q1/2D).

Rule, S, Barreto, WG, Briones, J, Carella, AM, Casasnovas, O, Pocock, C, Wendtner, CM, Zaja, F, Robson, S, MacGregor, L, Tschopp, RR, Nick, S, Dreyling, M. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase Ill MabCute study. HAEMATOLOGICA. 2022; 107(2)DOI:10.3324/haematol.2020.274803. PMID:34134469. IF:10.100(Q1/2D).

Wieduwilt, MJ, Metheny, L, Zhang, MJ, Wang, HL, Estrada-Merly, N, Marks, DI, Al-Homsi, AS, Muffly, L, Chao, N, Rizzieri, D, Gale, RP, Gadalla, SM, Cairo, M, Mussetti, A, Gore, S, Bhatt, VR, Patel, SS, Michelis, FV, Inamoto, Y, Badawy, SM, Copelan, E, Palmisiano, N, Kharfan-Dabaja, MA, Lazarus, HM, Ganguly, S, Bredeson, C, Perez, MAD, Cassaday, R, Savani, BN, Ballen, K, Martino, R, Wirk, B, Bacher, U, Aljurf, M, Bashey, A, Murthy, HS, Yared, JA, Aldoss, I, Farhadfar, N, Liu, HT, Abdel-Azim, H, Waller, EK, Solh, M, Seftel, MD, van der Poel, M, Grunwald, MR, Liesveld, JL, Kamble, RT, McGuirk, J, Munker, R, Cahn, JY, Lee, JW, Freytes, CO, Krem, MM, Winestone, LE, Gergis, U, Nathan, S, Olsson, RF, Verdonck, LF, Sharma, A, Ringden, O, Friend, BD, Cerny, J, Choe, H, Chhabra, S, Nishihori, T, Seo, S, George, B, Baxter-Lowe, LA, Hildebrandt, GC, de Lima, M, Litzow, M, Kebriaei, P, Hourigan, CS, Abid, MB, Weisdorf, DJ, Saber, W. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances. 2022; 6(1)DOI:10.1182/bloodadvances.2021004916. PMID:34547770. IF:7.500(Q1/2D).

Mikulska, M, Knelange, N, Nicolini, LA, Tridello, G, Santarone, S, Di Bartolomeo, P, de la Camara, R, Cuellar, C, Velardi, A, Perruccio, K, Ljungman, P, Zaucha, J, Piekarska, A, Basak, G, Karakulska-Prystupiuk, E, Angelucci, E, Ciceri, F, Lupo-Stanghellini, MT, Fouillard, L, Garcia-Cadenas, I, Menconi, M, Blau, IW, Nassi, L, Cesaro, S, Styczynski, J. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients - Study of infectious diseases working party of EBMT. JOURNAL OF INFECTION. 2022; 84(1)DOI:10.1016/j.jinf.2021.10.024. PMID:34757138. IF:28.200(Q1/1D).

Serna, N, Falgas, A, Garcia-Leon, A, Unzueta, U, Nunez, Y, Sanchez-Chardi, A, Martinez-Torro, C, Mangues, R, Vazquez, E, Casanova, I, Villaverde, A. Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials. Pharmaceutics. 2022; 14(1)DOI:10.3390/pharmaceutics14010192. PMID:35057088. IF:5.400(Q1/2D).

Wierda, WG, Allan, JN, Siddiqi, T, Kipps, TJ, Opat, S, Tedeschi, A, Badoux, XC, Kuss, BJ, Jackson, S, Moreno, C, Jacobs, R, Pagel, JM, Flinn, I, Pak, Y, Zhou, C, Szafer-Glusman, E, Ninomoto, J, Dean, JP, James, DF, Ghia, P, Tam, CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(34)DOI:10.1200/JCO.21.00807. PMID:34618601. IF:50.739(Q1/1D).